Notizia

The nasal antidepressant of Johnson & Johnson leads to FDA committee The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for the discoveries in novel therapies for the disorder. The intranasal, esketamine would be one of the first new approaches to treat the refrac...

Raynaud's Disease (RD), also called Raynaud's phenomenon, is a rare disorder of the blood vessels. The symptoms include when one is feeling cold or feeling stressed in some areas of the body like fingers and toes, blood can't reach to the epidermis (surface of the skin) and the affected areas turn wh...

https://www.slideshare.net/DelveInsight/acromegaly-and-gigantism-therapeutics-2?qid=ed224bb4-073c-4c5a-acdc-a02b6bad09d7&v=&b=&from_search=6 Acromegaly :-The excessive Growth Hormone comes from benign tumors on the pituitary. It is rare but serious hormonal disorder.

Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural...

Relations between the central nervous system and the trillions of bacteria in the gut are being targeted for research. What we know so far is based on studies indicating links between specific gut bacteria, their metabolites and neurological symptoms. However these links do not prove cause and effect. Many studies ...

FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and samidorphan. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed im...